Reason for request
Inclusion
Clinical Benefit
Clinical Added Value
| no clinical added value |
NEVANAC 1 mg/ ml, eye drops, suspension does not offer any improvement in actual benefit (IAB V) over standard management of postoperative macular oedema associated with cataract surgery in diabetic patients. |
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
8NJHNR4c3x6gDf3k
Listen
